As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Monopar Therapeutics. The largest reported stake is Janus Henderson Group Plc's, at 19.5%. 12 filings are on record since August 14, 2025 (Schedule 13G/A, November 14, 2025).
Sell to companies like Monopar Therapeutics? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 330,149 · Shared voting: 0 · Sole dispositive: 338,133 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-27
- · Reporting person: Adage Capital Management, L.P. · Sole voting: 0 · Shared voting: 324,195 · Sole dispositive: 0 · Shared dispositive: 324,195 · SCHEDULE 13G/A, 2026-08-12
- · Reporting person: Saturn V Capital Management LP · Sole voting: 0 · Shared voting: 313,384 · Sole dispositive: 0 · Shared dispositive: 313,384 · SCHEDULE 13G/A, 2026-08-12
- · Holder: Saturn V Capital Management LP · Percent: 5.2% · SCHEDULE 13G
- · Holder: Adage Capital Management, L.P. · Percent: 6.23% · SCHEDULE 13G/A
Monopar Therapeutics has 12 Schedule 13D or 13G filings on record since 2025-08-14. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Janus Henderson Group Plc | 19.5% | 1,287,368 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| RA Capital Management, L.P. | 9.9% | 667,632 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| AstraZeneca PLC | 7.8% | 522,667 | SCHEDULE 13G/A, 2026-02-06 | 2025-12-31 |
| BlackRock, Inc. | 5.03% | 338,133 | SCHEDULE 13G, 2026-10-27 | 2026-09-30 |
| Adage Capital Management, L.P. | 4.76% | 324,195 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| Saturn V Capital Management LP | 4.7% | 313,384 | SCHEDULE 13G/A, 2026-08-12 | 2026-06-30 |
| Tactic Pharma LLC | 4.5% | 0 | SCHEDULE 13D/A, 2026-01-30 | 2026-01-28 |
Holding shares or following this stake? See who's behind Monopar Therapeutics and the warning signs.
Free to see. No signup.
Keep reading
More on Monopar Therapeutics and the records around it.
Monopar Therapeutics elsewhere on the record
Companies that share a holder
- Saturn V Capital Management LP also filed stake reports on 2 other companies: Immix Biopharma, Inc. (Feb 2026), X4 Pharmaceuticals, Inc. (Feb 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
- JANUS HENDERSON GROUP PLC also filed stake reports on 104 other companies: SURGERY PARTNERS, INC. (Nov 2026), EYEPOINT, INC. (Sep 2026), TELEFLEX INCORPORATED (Sep 2026)
Watch Monopar Therapeutics
Get an email when Monopar Therapeutics files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Monopar Therapeutics?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Monopar Therapeutics: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Monopar Therapeutics covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 330,149 | 0 | 338,133 | 0 | SCHEDULE 13G, 2026-10-27 |
| Adage Capital Management, L.P. | 0 | 324,195 | 0 | 324,195 | SCHEDULE 13G/A, 2026-08-12 |
| Robert Atchinson | 0 | 324,195 | 0 | 324,195 | SCHEDULE 13G/A, 2026-08-12 |
| Phillip Gross | 0 | 324,195 | 0 | 324,195 | SCHEDULE 13G/A, 2026-08-12 |
| Saturn V Capital Management LP | 0 | 313,384 | 0 | 313,384 | SCHEDULE 13G/A, 2026-08-12 |
| Xiaoying Tian | 0 | 313,384 | 0 | 313,384 | SCHEDULE 13G/A, 2026-08-12 |
The latest filing identifies Monopar Therapeutics by CUSIP 61023L207 and gives its principal executive office as 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091 (SCHEDULE 13G, 2026-10-27).
What the percentages are based on
Aggregate of all Reporting Persons: 4.68%+ Saturn V Capital Management LP - 4.68%+* Xiaoying Tian - 4.68%+** * Saturn acts as the investment manager for the Clients who hold the Shares described herein and referred to above. As a result, Saturn possesses the power to vote and dispose or direct the disposition of all the Shares beneficially owned by the Clients.Saturn V Capital Management LP, SCHEDULE 13G/A, 2026-08-12
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Janus Henderson Group Plc | 19.2% | SCHEDULE 13G/A |
| 2025-09-24 | Tactic Pharma LLC | 7.5% | SCHEDULE 13D/A |
| 2025-11-14 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
| 2025-11-14 | Janus Henderson Group Plc | 19.5% | SCHEDULE 13G/A |
| 2026-01-30 | Tactic Pharma LLC | 4.5% | SCHEDULE 13D/A |
| 2026-02-06 | AstraZeneca PLC | 7.8% | SCHEDULE 13G/A |
| 2026-02-17 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
| 2026-05-13 | Adage Capital Management, L.P. | 6.23% | SCHEDULE 13G/A |
| 2026-05-15 | Saturn V Capital Management LP | 5.2% | SCHEDULE 13G |
| 2026-08-12 | Adage Capital Management, L.P. | 4.76% | SCHEDULE 13G/A |
| 2026-08-12 | Saturn V Capital Management LP | 4.7% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock, Inc. | 5.03% | SCHEDULE 13G |
Questions about who owns Monopar Therapeutics
Who owns Monopar Therapeutics?
On this page, 4 holders' latest ownership filings report 5% or more of Monopar Therapeutics: Janus Henderson Group Plc (19.5%, Schedule 13G/A, filed 2025-11-14), RA Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-02-17), AstraZeneca PLC (7.8%, Schedule 13G/A, filed 2026-02-06) and BlackRock, Inc. (5.03%, Schedule 13G, filed 2026-10-27).
Who are the largest shareholders of Monopar Therapeutics?
By the share each holder's latest filing reports, the largest holders of Monopar Therapeutics on this page are Janus Henderson Group Plc (19.5%), RA Capital Management, L.P. (9.9%) and AstraZeneca PLC (7.8%).
When did Janus Henderson Group Plc buy into Monopar Therapeutics?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group Plc on this page is the Schedule 13G/A, filed 2025-08-14, reporting 19.2%; its latest, Schedule 13G/A filed 2025-11-14, reports 19.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Monopar Therapeutics. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.